CrystalsFirst is setting new standards as one of the best CROs in the field for Innovative Solutions in Drug Development. Recognized by Fierce Biotech for its pioneering achievements, CrystalsFirst is transforming drug discovery through its advanced MAGNET platform. This platform demonstrates the company’s commitment to excellence, combining breakthrough technologies and deep expertise to address some of the most complex challenges in drug design.

Key achievements of the MAGNET platform include:

• Target Enablement: Successfully enabling over 40 drug targets, broadening therapeutic possibilities and pushing the frontiers of drug discovery.
• SmartSoak® Technology: Accelerating the path to co-structures, significantly reducing the time required for target validation.
• FragAI for Molecular Design: Leveraging proprietary generative AI to design and optimize molecular structures, enhancing both efficiency and precision in the early stages of drug discovery.

These advancements underscore CrystalsFirst’s commitment to redefining industry standards and accelerating the drug discovery process with next-generation technologies. This recognition from Fierce Biotech reinforces CrystalsFirst’s role as a leader in innovative drug discovery solutions, positioning the company at the forefront of the industry.

With a focus on the future, CrystalsFirst aims to further expand its pioneering work by advancing into targeted protein degradation and, more broadly, proximity-induced modalities. This new direction reflects CrystalsFirst’s commitment to evolving with cutting-edge science and applying innovative approaches shaping the industry.

2024 Fierce CRO Awards Finalists